Actively Recruiting
Evaluating Combined Finerenone and Empagliflozin Treatment Compared to Usual Care in Hospitalized Heart Failure Patients
Led by Colorado Prevention Center · Updated on 2026-09-10
1500
Participants Needed
140
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.
CONDITIONS
Brief Title
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Research Team
M
Marc Bonaca
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here